Assembly Bill A9075

2023-2024 Legislative Session

Requires health insurance policies to cover comprehensive genetic screening for ovarian and prostate cancers

download bill text pdf

Sponsored By

Current Bill Status - In Assembly Committee

  • Introduced
    • In Committee Assembly
    • In Committee Senate
    • On Floor Calendar Assembly
    • On Floor Calendar Senate
    • Passed Assembly
    • Passed Senate
  • Delivered to Governor
  • Signed By Governor

Do you support this bill?

Please enter your contact information

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.
Actions

2023-A9075 (ACTIVE) - Details

See Senate Version of this Bill:
S927
Current Committee:
Assembly Insurance
Law Section:
Insurance Law
Laws Affected:
Amd §§3216, 3221 & 4303, Ins L
Versions Introduced in Other Legislative Sessions:
2015-2016: A291
2017-2018: A1807
2019-2020: A5727, S4768
2021-2022: A425, S105

2023-A9075 (ACTIVE) - Summary

Requires health insurance policies to cover comprehensive genetic screening and FDA approved biomarker testing for ovarian and prostate cancers.

2023-A9075 (ACTIVE) - Bill Text download pdf 

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                   9075
 
                           I N  A S S E M B L Y
 
                             February 6, 2024
                                ___________
 
 Introduced  by M. of A. SEPTIMO -- read once and referred to the Commit-
   tee on Insurance
 
 AN ACT to amend the insurance  law,  in  relation  to  requiring  health
   insurance  policies  to  fully cover comprehensive genetic testing and
   FDA approved biomarker testing for ovarian and prostate cancers
 
   THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section  1. This act shall be known and may be cited as the "Ana Lucia
 act".
   § 2. Paragraph 11-a of subsection (i) of section 3216 of the insurance
 law is amended by adding a new subparagraph (C) to read as follows:
   (C) (I) SUCH POLICY SHALL PROVIDE ADDITIONAL FULL COVERAGE FOR COMPRE-
 HENSIVE GENETIC TESTING AND FDA APPROVED  TESTING  BASED  ON  FAMILY  OR
 PERSON'S  HISTORY FOR PROSTATIC AND OVARIAN CANCER WHEN RECOMMENDED BY A
 DOCTOR, A BOARD-CERTIFIED GENETICIST OR A BOARD-CERTIFIED GENETIC  COUN-
 SELOR.  SUCH COVERAGE SHALL ALSO BE PROVIDED AFTER THE PATIENT'S INITIAL
 DIAGNOSIS.  PATIENTS  NEED  TO KNOW IF THEY CARRY THE GENETIC OR INHERI-
 TANCE MUTATION, WHICH CAN HELP TO DETERMINE POSSIBLE TREATMENTS. GENETIC
 SCREENING SHALL BE COVERED FOR PROSTATE  AND  OVARIAN  CANCER  PATIENTS'
 FAMILY  MEMBERS.  THE  GENETIC  RESULT  SHALL NOT BE USED AGAINST FAMILY
 MEMBERS THAT CARRY THE GENETIC OR  INHERITANCE  MUTATION  FOR  INSURANCE
 COVERAGE PURPOSES.
   (II) ALL COSTS ASSOCIATED WITH SUCH ADDITIONAL FULL COVERAGE SHALL NOT
 BE  SUBJECT  TO  ANNUAL  DEDUCTIBLES  AND COINSURANCE BUT SHALL BE BORNE
 SOLELY BY THE INSURER.
   § 3. Paragraph 11-a of subsection (l) of section 3221 of the insurance
 law is amended by adding a new subparagraph (C) to read as follows:
   (C)(I) SUCH POLICY SHALL PROVIDE ADDITIONAL FULL COVERAGE FOR  COMPRE-
 HENSIVE  GENETIC  TESTING  AND  FDA  APPROVED TESTING BASED ON FAMILY OR
 PERSON'S HISTORY FOR PROSTATIC AND OVARIAN CANCER WHEN RECOMMENDED BY  A
 DOCTOR,  A BOARD-CERTIFIED GENETICIST OR A BOARD-CERTIFIED GENETIC COUN-
 SELOR.  SUCH COVERAGE SHALL ALSO BE PROVIDED AFTER THE PATIENT'S INITIAL
 DIAGNOSIS. PATIENTS NEED TO KNOW IF THEY CARRY THE  GENETIC  OR  INHERI-
 TANCE MUTATION, WHICH CAN HELP TO DETERMINE POSSIBLE TREATMENTS. GENETIC
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.